Enzyme-responsive hybrid prodrug of nitric oxide and hydrogen sulfide for heart failure therapy

Qi Liu; Guangbo Ji; Yushu Chu; Tian Hao; Meng Qian; Qiang Zhao

doi:10.1039/d2cc02267b

Enzyme-responsive hybrid prodrug of nitric oxide and hydrogen sulfide for heart failure therapy

Chem Commun (Camb). 2022 Jun 30;58(53):7396-7399. doi: 10.1039/d2cc02267b.

Authors

Qi Liu¹, Guangbo Ji¹, Yushu Chu¹, Tian Hao¹, Meng Qian¹, Qiang Zhao¹

Affiliation

¹ State key Laboratory of Medicinal Chemical Biology, Haihe Laboratory of Sustainable Chemical Transformations, Key Laboratory of Bioactive Materials (Ministry of Education), Frontiers Science Center for Cell Responses, College of Life Sciences, Nankai University, Tianjin 300071, China. qiangzhao@nankai.edu.cn.

PMID: 35686984
DOI: 10.1039/d2cc02267b

Abstract

A hybrid prodrug was synthesized to realize the combined delivery of nitric oxide and hydrogen sulfide. The NO-H₂S donor can release nitric oxide and hydrogen sulfide step by step in response to the endogenous enzymes β-galactosidase and carbonic anhydrase, providing potent therapeutic efficacy for heart failure post- myocardial infarction.

MeSH terms

Cardiotonic Agents / therapeutic use
Diuretics
Enzyme Inhibitors / therapeutic use
Heart Failure* / drug therapy
Humans
Hydrogen Sulfide* / pharmacology
Hydrogen Sulfide* / therapeutic use
Myocardial Infarction*
Nitric Oxide / therapeutic use
Prodrugs* / pharmacology
Prodrugs* / therapeutic use

Substances

Cardiotonic Agents
Diuretics
Enzyme Inhibitors
Prodrugs
Nitric Oxide
Hydrogen Sulfide